Adjuvant chemotherapy with immune checkpoint inhibitors during the perioperative period of lung cancer improves a patient’s prognosis, even with PD-L1 expression levels as low as 1%, and this effect becomes more pronounced when the expression levels exceed 50%32. The gene discussed is CD274; the disease is lung cancer.